Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice

Proteolysis-targeting chimeras for targeting protein for degradation

(2019) Jianguo Qi et al.   Future Medicinal Chemistry

PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery

(2018) Shanshan Gu et al.   BIOESSAYS

DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective

(2018) Ankita Pathak et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Temporal and regional progression of Alzheimer’s disease-like pathology in 3xTg-AD mice

(2018) Ramona Belfiore et al.   AGING CELL

MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells

(2015) L. Beke et al.   BIOSCIENCE REPORTS

Identification of a DYRK1A Inhibitor that Induces Degradation of the Target Kinase using Co-chaperone CDC37 fused with Luciferase nanoKAZ

(2015) Rie Sonamoto et al.   Scientific Reports

Administration of a selective β2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease

(2014) Caterina Branca et al.   NEUROBIOLOGY OF AGING

Glucocorticoids Exacerbate Cognitive Deficits in TDP-25 Transgenic Mice via a Glutathione-Mediated Mechanism: Implications for Aging, Stress and TDP-43 Proteinopathies

(2013) A. Caccamo et al.   JOURNAL OF NEUROSCIENCE

Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans

(2013) Rafael De la Torre et al.   MOLECULAR NUTRITION & FOOD RESEARCH

Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome

(2012) Xavier Altafaj et al.   NEUROBIOLOGY OF DISEASE

β-Carboline Compounds, Including Harmine, Inhibit DYRK1A and Tau Phosphorylation at Multiple Alzheimer's Disease-Related Sites

(2011) Danielle Frost et al.   PLoS One

Soluble amyloid  -protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration

(2011) M. Jin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation

(2010) David O Azorsa et al.   BMC GENOMICS

Activation, regulation, and inhibition of DYRK1A

(2010) Walter Becker et al.   FEBS Journal

The role of DYRK1A in neurodegenerative diseases

(2010) Jerzy Wegiel et al.   FEBS Journal

A  Oligomers Cause Localized Ca2+ Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines

(2010) H. Zempel et al.   JOURNAL OF NEUROSCIENCE

Why Pleiotropic Interventions are Needed for Alzheimer's Disease

(2010) Sally A. Frautschy et al.   MOLECULAR NEUROBIOLOGY

The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome

(2008) Jerzy Wegiel et al.   ACTA NEUROPATHOLOGICA

Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome

(2008) Fei Liu et al.   FASEB JOURNAL

Multi-target-Directed Ligands To Combat Neurodegenerative Diseases

(2008) Andrea Cavalli et al.   JOURNAL OF MEDICINAL CHEMISTRY

Multifunctional receptor-directed drugs for disorders of the central nervous system

(2008) Jerry J. Buccafusco   Neurotherapeutics

Multifunctional neuroprotective derivatives of rasagiline as anti-alzheimer’s disease drugs

(2008) Orly Weinreb et al.   Neurotherapeutics

Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer’s disease

(2007) Soo-Ryoon Ryoo et al.   JOURNAL OF NEUROCHEMISTRY